Back to results
US 12,577,249 B2Granted
GCN2 and perk kinase inhibitors and methods of use thereof
AssigneeDeciphera Pharmaceuticals, LLC
InventorsYu Mi Ahn, Gada Al-Ani, Daniel L. Flynn, Salim Javed, Patrick Kearney, Bertrand LeBourdonnec, Kristen Stoltz, Jeffery Zwicker
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
Claims28
A compound represented by Formula I-A:
- or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein:
- X1 and X3 are each independently selected from the group consisting of CH and N;
- X2 is selected from the group consisting of NR6, O, and S;
- R1, R2, and R3 are each independently selected from the group consisting of H, halogen, cyano, and alkoxy;
- R4 is selected from the group consisting of halogen, alkoxy and alkyl;
- R5 is selected from the group consisting of H, halogen and alkyl;
- R6 is selected from the group consisting of H, alkyl, alkenyl, alkenylalkyl, alkynyl, alkynylalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl;
- and
- R7 is selected from the group consisting of H, alkyl, and acyl.
6 more elements
A compound selected from the group consisting of:
- and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof.
Dependencies are inferred from the claim text.